anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The aldehyde dehydrogenase 2 (ALDH2) rs671 polymorphism commonly exists in the East Asian populations and is associated with high risks of cardiovascular disease (CVD). However, the cellular and molecular mechanisms that underlie the ALDH2 rs671 mutant-linked high CVD remain elusive. Here, we show that macrophages derived from human ALDH2 rs671 carriers and ALDH2 knockout mice exhibited an enhanced pro-inflammatory macrophage phenotype and an impaired anti-inflammatory macrophage phenotype. Transplanting bone marrow from ALDH2-/-ApoE-/- to ApoE-/- mice significantly increased atherosclerotic plaque growth and pro-inflammatory macrophage polarization in vivo. Mechanistically, ALDH2 inhibited activation of the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway in macrophages. Pharmacological inhibition of cGAS by RU.521 completely neutralized ALDH2-deficiency-induced macrophage polarization. In-depth mechanistic investigation showed that ALDH2 accelerated cGAS K48-linked polyubiquitination degradation at lysine 282 in macrophages by reducing the interaction between ubiquitin-specific protease 14 (USP14) and cGAS, mainly through its enzymatic role in mitigating 4-hydroxy-2-nonenal (4-HNE) accumulation. Consistently, USP14 knockdown in bone marrow cells alleviated proinflammatory responses in macrophages and protected against atherosclerosis. Our findings provide new mechanistic insights of ALDH2 deficiency-associated proinflammation and atherosclerosis and new therapeutic and preventive paradigms for treatment of atherosclerosis-associated CVD.
<P>PROBLEM TO BE SOLVED: To enable to easily obtain and preset an appropriate test protocol for each test by sharing test protocols among medical diagnostic imaging apparatuses when a wide variety of tests are performed with medical diagnostic imaging apparatuses.  <P>SOLUTION: X-ray diagnostic imaging apparatuses 101A and 102B of medical institutions A and B, respectively, and an information delivery server 201 are linked by a wide-area network 301. Test protocols including information on X-ray diagnostic imaging are recorded in the server 201, and the server searches for and provides a test protocol upon request of the X-ray diagnostic imaging apparatuses 101A and 102B. Consequently, each of the diagnostic apparatuses 101A and 102B can use test protocols established by the other apparatus besides test protocols established by itself. Since the server 201 has a search function, the diagnostic apparatuses 101A and 102B are able to easily obtain any information among the recorded test protocols.  <P>COPYRIGHT: (C)2004,JPO
This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked.

  1. Triamterene and hydrochlorothiazide tablets are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone. 
  2. Triamterene and hydrochlorothiazide is also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked (e.g., patients on concomitant digitalis preparations, or with a history of cardiac arrhythmias, etc.).



Triamterene and hydrochlorothiazide may be used alone or in combination with other antihypertensive drugs such as beta-blockers. Since triamterene and hydrochlorothiazide may enhance the actions of these drugs, dosage adjustments may be necessary.
Growing evidence indicates that poor sleep harms health. Early to bed and early to rise is considered as a healthy lifestyle in Chinese population. The current study aimed to examine the effects of sleep habits on acute myocardial infarction (AMI) risk and severity of coronary artery disease (CAD) in Chinese population from two centers. A total of 873 patients including 314 with AMI were recruited from the inpatient cardiology department of the Affiliated Jiangning Hospital and the First Affiliated Hospital of Nanjing Medical University. 559 controls included 395 CAD cases and 164 non-CAD cases. Investigators used a 17-item sleep factors questionnaire (SFQ) to evaluate sleep habits comprehensively by face-to-face interview. The severity of CAD was assessed by Gensini score in AMI and CAD groups. The effects of sleep factors on AMI risk and Gensini score were examined by unconditional logistic regression. The timing of sleep (24:00 and after), sleep duration (\<6h) and frequency of night-time waking (3 times) increased the risk of AMI. In subjects with age ≤60 years, daytime napping reduced the risk of AMI. The correlation between sleep quality and AMI became insignificant after subgroup analysis by age. Short sleep duration also increased the risk of high Gensini score.
The present invention relates to a green type bag for reducing weight, which belongs to a traditional Chinese medicine bag used externally. The present invention comprises the following raw material medicine by weight parts: 8 to 15 parts of radix paeoniae alba, 9 to 13 parts of American ginseng, 10 to 18 parts of Jiazhu, 10 to 15 parts of cordyceps, 10 to 15 parts of rhizoma atractylodis macrocephalae, 6 to 10 parts of radix bupleuri and 10 to 15 parts of poria. The present invention has the advantages of channel dredging, no pain and no adverse reaction and has the functions of fat decomposition and endocrine regulation of human bodies. Clinical practice shows that the present invention is suitable for obesity people at all ages to use and has obvious effects on losing weight. With no damage and no side effect to human bodies, the present invention belongs to a green type bag for losing weight. After body weight is reduced, skin is not relax. Waist circumference and skin of a belly and a stomach are compact, and the skin does not pile up any more in the future, so the present invention has the advantages of perfect figure shaping and no rebound.
Tralement is supplied as a single-dose vial and multiple-dose vial for admixture use only. It is not for direct intravenous infusion. Prior to administration, Tralement must be transferred to a separate parenteral nutrition container and used as an admixture in parenteral nutrition solution.

The final parenteral nutrition solution is for intravenous infusion into a central or peripheral vein. The choice of a central or peripheral venous route should depend on the osmolarity of the final infusate. Solutions with osmolarity of 900 mOsmol/L or greater must be infused through a central catheter [see Warnings and Precautions (5.2)].
Up to a third of middle-aged people living with HIV infection (PLWH) experience falls each year. Falls are the most common cause of non-fatal injury in the US and the cost from emergency department visits and hospitalizations are enormous. PLWH are more susceptible to falls and their serious consequences because 1) despite control of HIV viremia, inflammation persists and underlies HIV-associated comorbidities and complications that occur at a relatively young age (so-called premature aging); 2) specific comorbidities (e.g., neuropathy, osteoporosis) and complications (e.g., frailty and impaired physical function) make falls more likely and recovery from them more difficult; 3) alcohol use exacerbates inflammation, and may increase risk for comorbidities and complications; and 4) alcohol use, illicit drug use and polypharmacy can increase the likelihood of a fall. Despite this, fall prevention has not been extensively studied among PLWH. Interventions are needed to address falls in PLWH but none have been tailored for this population. Understanding risk factors and targets for intervention among PLWH are essential; cohort studies can provide the information needed for intervention development.

This study is part the Consortia for HIV/AIDS and Alcohol-Related Research Trials (CHAART). It describes the continuation and expansion of a cohort that is one of three in the Uganda Russia Boston Alcohol Network for Alcohol Research Collaboration on HIV/AIDS (URBAN ARCH). The URBAN ARCH theme is to address consequences of alcohol use on HIV-associated comorbidities and complications to increase treatment availability and improve outcomes. In line with that theme the investigators will continue to follow and expand (to 400) an existing cohort of PLWH and a high prevalence of exposure to alcohol, illicit drugs, and polypharmacy (the Boston ARCH Cohort) in the Frailty, Functional impairment, Falls, and Fractures (4F study) to: (in 2 Primary Aims) 1) Test the associations between alcohol (and illicit drugs and polypharmacy) and falls (fractures secondarily); and 2) Test the associations between alcohol (and illicit drugs and polypharmacy) and acute healthcare utilization (emergency department use and hospitalization for falls and fractures). The investigators will examine the role frailty plays in these associations between alcohol, drugs and medications and the aforementioned clinical and utilization outcomes. By achieving these aims the investigators will gain substantially greater understanding of these comorbidities and complications in PLWH exposed to alcohol and other psychoactive substances; this knowledge will serve to inform the development of ways to identify, prevent and manage falls, fractures, frailty and functional impairment.
PURPOSE:To increase an apparent hair volume with high durability sustaining the hair-tonic and hair-growing effect by using a combination of a blood circulation accelerator with a naphthalenesulfonic acid and/or a benzophenonesulfonic acid. CONSTITUTION:This hair-tonic and hair-growing agent comprises a blood circulation accelerator, an organic solvent (particularly ethanol, or a combination thereof with another organic solvent), a naphthalenesulfonic acid and/or a benzophenonesulfonic acid. This agent has preferably a pH of 2-11. Further, it is preferred that an organic acid or its salt is admixed. The blood circulation agent has the hair-tonic and hair-growing effect through the actions not only of circulation acceleration but also of topical stimulation, trichocyte activation and antiinflammation. For example, dl-alpha-tocopherol acetate or biotin can be cited. This hair-growing agent has excellent hair-dressing effect because it can give hairs elasticity and stiffness and develop an action to increase the apparent hair volume.
In terms of incidence, prevalence, morbidity, and economic costs, coronary artery disease represents a number 1 public health concern. Omacor®/Lovaza® is an effective, and very safe mix of PO-3A, and the drug is currently approved by the Federal authorities for the drug management of post-infarction patients with high blood triglycerides. Despite significant progress in the prevention and treatment of vascular disease in the Western World in the past two decades, national statistics indicate that the incidence and prevalence of heart disease has been increasing steadily. Given the growing length of CAD progression, it is pertinent that many more patients will yield extra benefit from Lovaza® on top of aggressive antiplatelet regimens and statin due to severity of their vascular disease. Therefore, mild antiplatelet properties of PO-3A will be a highly desirable and attractive commodity of this medication.

We believe that Omacor®/Lovaza® is ideally positioned for the chronic management of CAD as a safe, efficient, and "gentle" agent with no harmful interactions with statins or aspirin. Also considering low clinical incidence of aspirin-induced interactions with other classes of drugs, Lovaza® may fit nicely into a standard cocktail for diabetes, hypertension, depression, arrhythmias, and heart failure management of CAD patients, which will expand the drug utilization. However, platelet-related effects of Lovaza® on top of aspirin and statin in patients with stable coronary disease are not known, but may be important due to the high incidence of aspirin resistance and heavy burden of thrombin activation in such patients. We have a large pool of patients with documented CAD (300-350/annum), and we will be able to enroll relatively large amount of quality patients fast.
Disclosed herein are methods and systems for determining microsatellite instability. In some embodiments, the disclosed methods and systems are used for determining whether a cancer patient has high microsatellite instability (MSI-H). MSI-H patients have remarkably good responses to immunotherapy, such as checkpoint inhibitors immunotherapy. Therefore, the disclosed methods and systems can be used for identifying MSI-H and thus, patients as candidates for immunotherapy. In turn, the disclosed methods and systems can be used to predict responsiveness to immunotherapy. In some embodiments, the methods further include providing an immunotherapy to the MSI-H patient. Also disclosed are vaccines and compositions.
The study includes two steps. Firstly, translation of the questionnaire into Cantonese, followed by cross-cultural adaptation. Ten Chinese Medicine Practitioners (CMPs) and 30 patients will be recruited from the community and the outpatient clinics of Hong Kong Baptist University (HKBU) to evaluate the Constitution in TCM Questionnaire (For Old Person) (Cantonese version) (CTCMQ-C) for content validity by the cognitive debriefing interviews. The content validity indices (CVI) of clarity, relevance and appropriateness of each item of the questionnaire rated by CMPs and patients will be quantified. The interpretations of items and suggestions of rewording by the patients and CMPs will be analyzed qualitatively to identify any item of the questionnaire that is not valid for the Chinese population in Hong Kong. Secondly following the validation study, 264 patients will be recruited. A validated CTCMQ-C will then be generated and will be endorsed by expert panel to use in the subsequent cross-sectional and cohort studies to evaluate the preventive effect with Chinese Medicine approaches. The psychometric properties including construct validity by scaling assumptions, confirmatory factor analysis (CFA) and reliability of the CTMCQ-C will also be tested.
All families referred to the Healthy Weight Clinic intervention arm will be scheduled for a 30-45 minute orientation clinic visit to orient the child and family to the program. During this visit, the family will meet with the community health worker who will provide a schedule of clinic visits and dietitian contacts. The community health worker will assess the child's social and environmental context to allow treatment tailoring. For the first 6 months, each family will be asked to attend two clinic visits per month and complete weekly 20-30 minute contacts with the dietitian via telephone. The program aims to deliver approximately 30 contact hours in the 6-month period. This will be followed by monthly visits to the Healthy Weight Clinic and monthly calls with their dietitian.
The invention discloses a premix auxiliary material. The premix auxiliary material comprises polyvinylpyrrolidone, glyceryl behenate, and a pharmaceutical adjuvant filler and a pharmaceutical adjuvant disintegrant, wherein the weight ratio of the filler, the disintegrant, the polyvinylpyrrolidone and the glyceryl behenate is (80-98.5):(10-0.5):(5-0.5):(5-0.5). The premix auxiliary material comprising the polyvinylpyrrolidone and the glyceryl behenate is good in fluidity, strong in compressibility and good in lubricating effect. The mixing uniformity, the medicine content, the tablet hardness, and the like would not change with prolongation of the total mixing time. The premix auxiliary material is prone to enlargement. Indexes comprising fluidity, the Carr's index, compressibility, friability, etc. of the premix auxiliary material provided by the invention are superior to corresponding indexes of auxiliary materials mixed physically. Uncontrollable factors of the technology are reduced, thus facilitating large-scale production. The premix auxiliary material can be used for direct compression of tablets or encapsulation of capsules.
BACKGROUND: Microvascular decompression (MVD), the standard surgical approach for hemifacial spasm (HFS), can be divided into the interposition and transposition methods. Although the risk of HFS recurrence following interposition has been reported, there is limited data comparing long-term outcomes between both methods performed by a single surgeon. This study aimed to investigate the efficacy of MVD techniques on HFS by comparing surgical outcomes performed by a single surgeon in a single-center setting.
METHODS: A total of 109 patients who underwent MVD were analyzed and divided into the transposition (86 patients) and interposition (23 patients) groups. Postoperative outcomes at 1 month and 1 year were assessed and compared, including rates of spasm relief, complications, and recurrence.
RESULTS: Outcome assessment revealed higher rates of early spasm relief in the interposition group (66.3% vs. 100%, transposition vs. interposition, respectively, p = 0.0004), although spasm relief at 1-year postoperatively was comparable between the two groups (84.9% vs. 95.7%, transposition vs. interposition, respectively, p = 0.2929). No significant differences were observed in complication and recurrence rates. Kaplan-Meier analysis demonstrated no significant differences in the duration of spasm resolution by MVD method (p = 0.4347, log-rank test).
CONCLUSION: This study shows that both the transposition (Surgicel® and fibrin glue) and interposition (sponge) methods were excellent surgical techniques. The interposition method may achieve earlier spasm resolution compared to the transposition method.
CC-486 300 mg will be administered orally on days 1-14 of a 28-day cycle. Venetoclax will be administered days 1-3, with the following schema: 100 mg on day 1, 200 mg on day 2, 400 mg on day 3, and it will be continued at 400mg thereafter until day 28, the completion of cycle 1.
Water-insoluble, acid-soluble, film-forming modified polymers are prepared by esterifying polyvinyl alcohol, partially butyralized polyvinyl alcohol or a hydrolysed vinyl acetatecrotonic acid copolymer with monochloracetic acid, acetalizing the esterified product with an aliphatic aldehyde containing 2 to 4 carbon atoms, and aminating the esterified and acetalized product with a dialkylamine containing 1 to 4 carbon atoms in each alkyl radical. The esterification and acetalization may be effected in the presence of a mineral acid, e.g. hydrochloric or sulphuric acid, and the amination in the presence of an organic solvent, e.g. acetone or methanol.  Specified aldehydes are acetaldehyde, n-butyraldehyde and isobutyraldehyde. Specified amines are diethylamine, dipropylamine and dibutylamine. Examples describe the preparation of modified polymers by reacting diethylamine with intermediates prepared from monochloracetic acid and (1) polyvinyl alcohol and paraldehyde; a partial butyral of polyvinyl alcohol and (2) paraldehyde, (3) n-butyraldehyde and (4) isobutyraldehyde; and (5) a hydrolysed copolymer of vinyl acetate and crotonic acid and paraldehyde.  The modified polymers may be dissolved in organic solvents, e.g. ethyl acetate, acetone, methanol, ethanol, isopropanol and chloroform, and the compositions so obtained used for coating pharmaceutical tablets. Such coating compositions may also comprise colouring matter, e.g. b -carotene and titanium dioxide, polyethylene glycols, sweetening agents such as cyclohexylsulphamic acid and edible oils such as rape-seed and castor oils.ALSO:Pharmaceutical preparations for oral administration are coated with water-insoluble, acid-soluble, film-forming polymers prepared by esterifying polyvinyl alcohol, partially butyralized polyvinyl alcohol or a hydrolysed vinylacetate/crotonic acid copolymer with monochloracetic acid, acetalizing the esterified product with an aliphatic aldehyde containing 2 to 4 carbon atoms, and aminating the esterified and acetalized product with a dialkylamine containing 1 to 4 carbon atoms in each alkyl group.  In examples lactose/dextrin tablets are coated with polymers prepared by reacting diethylamine with the monochloracetic acid esters of the reaction products of (1) polyvinyl alcohol and paraldehyde; a partial butyral of polyvinyl alcohol and (2) paraldehyde, (3) n-butyraldehyde and (4) isobutyraldehyde; and (5) a hydrolysed copolymer of vinyl acetate and crotonic acid and paraldehyde.
Stroke is the disease with the highest mortality and disability in China, and the annual incidence of ischemic stroke is the highest. Atherosclerosis is the main cause of ischemic stroke. According to the theory of traditional Chinese medicine, the disease is closely related to the physical constitution of the individual. The main body constitution of the population in Lingnan area is phlegm dampness syndrome;Previous large cross-sectional studies have found that 65.3% of patients with ischemic stroke in Lingnan area have phlegm dampness syndrome. However, there is currently no biological evidence related to phlegm-dampness syndrome and ischemic stroke.In recent years, proteomics research technology has developed vigorously. The research samples have developed from blood obtained from minimally invasive to urine and saliva obtained non-invasively. Studies have found that urine proteins associated with AS include type I, type III collagen, 8-isoprostaglandin F2α, and saliva proteins include IL-1β, IL-6, TNF-α, and PGE2.Therefore, this research is dedicated to exploring the biological basis of phlegm-dampness syndrome in patients with ischemic stroke using proteomics research techniques of urine and saliva.
Is offspring skeletal muscle function and metabolism imprinted by regular maternal exercise? What offspring metabolome markers are altered with regular maternal exercise? The investigators will use a randomized design of 160 women to either exercise intervention (aerobic training, resistance training, or both) or usual care (controls). Infant cord tissue and blood will be sampled at birth while blood will be sampled at 1 month of age. Similarly, infant neuromotor and morphometric examinations will be performed at 1 month. and at 1-month of age via blood sample, neuromotor, and morphometric examinations. The rationale for the project is to elucidate the effects of maternal exercise on offspring health outcomes and determine specific metabolic targets predictive of offspring long-term disease risk.
Background: Handwriting is a complex skill that requires a combination of cognition, motor planning, and visuomotor integration. Various brain structures including the cerebral cortex, basal ganglia, and cerebellum are involved in learning and performing handwriting. Many neurological disorders impact these brain structures in unique ways, leading to distinct effects on handwriting. Changes in handwriting performance are a prominent feature of Parkinson disease (PD), ataxias, and other movement disorders. Handwriting analysis can serve as a tool to distinguish and monitor the progression of movement disorders. Patients suffering from PD exhibit impairments of previously learned motor skills, including handwriting. It has been demonstrated that patients in the early stages of Parkinson disease exhibit variations in handwriting when compared to healthy individuals. The current research will investigate kinematics, visuospatial adaptation, and learning in different movement disorders through handwriting analysis.

Data collection and Measurement techniques: The subject will be seated comfortably at a table with the digitalized tablet positioned to allow a natural writing position for the subject. Pen movements will be recorded using a non-inking pen and Wacom Cintiq 16-inch digitizing tablet connected to a laptop. A practice session will be provided to each participant to familiarize them with the inkless writing pen and tablet. Before each task, participants will be given instructions on how to perform the task. Participants will be instructed to complete several writing exercises aimed at evaluating various aspects of their handwriting skills. Each task will be repeated multiple times and the entire set of handwriting exercises will be completed within 30 minutes.